|
2006
October 26, 2006
Discovery Labs Restructures Loan Arrangement with
Quintiles
October 11, 2006
Discovery Labs Announces Topline Results of
Surfaxin® Phase 2 Clinical Trial for the Prevention and
Treatment of BPD
October 10, 2006
Surfaxin® Treated Premature infants Require Fewer
Re-intubations Compared with Animal Derived Surfactants
September 28, 2006
Discovery Labs Updates Progress on Manufacturing
Remediation and Surfaxin® FDA Regulatory Matters
July 28, 2006
Discovery Labs Reports Second Quarter
2006 Financial Results
July 26, 2006
Discovery Labs Announces Second Quarter
Conference Call and Webcast
June 27, 2006
Discovery Labs Reports Progress on its Surfactant
Manufacturing Remediation
June 21, 2006
Pulmonary Surfactant Commercial Expert Rejoins
Discovery Labs’ Executive Management Team
June 20, 2006
Discovery Labs Retains Jefferies & Company to Assist in the
Evaluation of Potential Strategic Alternatives
June 19, 2006
Discovery Labs to Present at the Jefferies Life
Sciences Conference
June 15, 2006
Discovery Labs’ Surfaxin® Granted Orphan Drug
Designation for the Prevention of Bronchopulmonary
Dysplasia
June 7, 2006
Discovery Labs Withdraws European Marketing
Application for Surfaxin®
May 10, 2006
Discovery Labs Reports First Quarter 2006
Financial Results
May 10, 2006
Discovery Labs Announces First Quarter Conference Call
and Webcast
May 5, 2006
Discovery Labs Announces Corporate Reorganization and
Personnel Reduction
April 24, 2006
Discovery Labs
Reports Surfaxin Manufacturing Issue
April 20, 2006
Discovery Labs
Provides Business and Financial Update
April 19, 2006
Discovery Labs
Secures $50 Million Committed Equity Financing Facility
April 12, 2006
Discovery Labs Provides Update on Surfaxin Regulatory
Progress
April 5, 2006
Discovery Labs
Receives Second Approvable Letter from FDA for Surfaxin
for RDS
March 30, 2006
Discovery Labs
Announces Preliminary Results of Phase 2 Clinical Trial
in ARDS
March 2, 2006
Discovery Labs to Present at the SG Cowen & Co. 26th
Annual Health Care Conference
February 24, 2006
Discovery Labs Grants 10 Neonatology Fellowship
Awards
February 23, 2006
Discovery Labs
Reports Fourth Quarter 2005 Financial Results and
Business Progress
February 17, 2006
Discovery Labs
Announces Fourth Quarter Conference Call and Webcast
February 10, 2006
Discovery Labs
to Present at the BIO CEO & Investor Conference
February 6, 2006
Discovery Labs Adds Senior Medical and Clinical
Executives with Broad Pulmonology Expertise
February 1, 2006
Discovery Labs to Present at the Brean Murray, Carret &
Company Annual Institutional Investor Conference
January
26, 2006
FDA Grants Discovery Labs’ Surfaxin® Fast Track
Designation for Prevention and Treatment of
Bronchopulmonary Dysplasia
January 12, 2006
Discovery Labs to Present at the JP Morgan Healthcare
Conference
2005
December 28, 2005
Discovery Labs’ Broadens Management Team - Hires Senior
Manufacturing and Quality Executives
December 28, 2005
Discovery Labs to Acquire Laureate Pharma’s
Manufacturing Operation in Totowa, N.J.
December 20, 2005
Discovery
Labs Announces Completion of $20.0 Million in Registered
Direct Offering
December 14, 2005
Discovery Labs
to Raise $20.0 Million in Registered Direct Offering
December 11, 2005
Discovery Labs
Forms a Strategic Alliance with Chrysalis Technologies
to Develop Aerosolized SRT for Respiratory Diseases
November 29, 2005
Discovery Labs
to Present at the First Albany Capital
Conference
November 3, 2005
Discovery Labs' Reports Third Quarter Earnings and
Business Progress
November 2, 2005
Discovery Labs
to Present at the SG Cowen 6th Annual Global Health Care
Conference
November 1, 2005
Discovery Labs
Announces Conference Call and Webcast
October 28, 2005
Discovery Labs'
Surfaxin Granted Orphan Drug Designation for the
Treatment of Bronchopulmonary Dysplasia
October 21, 2005
FDA
Accepts Discovery Labs' Complete Response to Approvable
Letter for Surfaxin
October 20, 2005
Discovery Labs'
Surfaxin Licensed in Italy by Dompe Farmaceutici
October 11, 2005
Discovery Labs
Files Universal Shelf Registration Statement
September 20, 2005
Discovery Labs to Present at the UBS Global Life
Sciences Conference
September 8, 2005
Discovery
Labs Completes Pilot Phase 2 Study of Investigational
Drug Aerosurf, its Aerosolized Surfactant Delivered via
Nasal CPAP
September 1, 2005
New
Health Economic Data Shows Cost Benefit in using
Surfaxin in RDS Babies
August 19, 2005
Discovery Labs
Provides Update on Status of Response to FDA Approvable
Letter for Surfaxin
August 18, 2005
Discovery Labs
Announces Conference Call and Webcast
August 15, 2005
Discovery Labs
Provides Status of Previously Submitted Response to FDA
Approvable Letter for Surfaxin
August 9, 2005
Discovery Labs
Selected as Founding Member of the NASDAQ Health Care
Index
August 2, 2005
Discovery Labs
Reports Second Quarter 2005 Financial Results and
Business Progress
July 29, 2005
Discovery Labs Submits Response to FDA Approvable Letter
for Surfaxin for RDS in Premature Infants
July 26, 2005
Discovery Labs Announces Second Quarter Conference Call
and Webcast
May 26, 2005
Discovery
Labs to Present at the Pacific Growth 2005 Life Sciences Conference
May 18, 2005
Discovery
Labs to Present at the Needham & Company Fourth Annual
Biotechnology Conference
May 18, 2005
New Data Shows Surfaxin Survival Benefit Continues
Through One Year of Life
April 27, 2005
Discovery
Labs Reports First Quarter 2005 Financial Results and
Business Progress
April 22, 2005
Discovery
Labs Announces First Quarter Conference Call and Webcast
April 4, 2005
Discovery
Labs’ Surfaxin (lucinactant) Phase 3 Results Published
in Pediatrics, the Official Journal of the American
Academy of Pediatrics
March 15, 2005
Discovery
Labs Reports Fourth Quarter 2004 Financial Results and
Business Progress
March 10, 2005
Discovery
Labs Announces Fourth Quarter Conference Call and
Webcast
March 9, 2005
Discovery
Labs to Present at the SG Cowen 25th Annual Health Care
Conference
February
25, 2005
Discovery
Labs Announces Completion of $29.1 Million Registered
Direct Offering
February
21, 2005
Discovery
Labs to Present at the Bio CEO & Investor Conference
February
18, 2005
Discovery Labs
to Raise Additional $2.6 Million in Registered Direct Offering
February
18, 2005
Discovery Labs
to Raise $26.5 Million in Registered Direct Offering
February
14, 2005
Discovery Labs Receives Approvable Letter from FDA for
Surfaxin® for
Respiratory Distress Syndrome in Premature Infants
February
1, 2005
Discovery Labs
Provides Update on FDA Pre-Approval Inspection
Activities Pertaining to Surfaxin® NDA Status
January
31, 2005
Discovery Labs Announces Conference Call to Provide an
Update on FDA Review of Surfaxin® NDA
January 28, 2005
Discovery Labs
to Present at the Brean Murray & Co. Annual
Institutional Investor Conference
January 6, 2005
Discovery Labs Initiates Two Phase 2 Clinical Trials -
Surfaxin® for Bronchopulmonary Dysplasia and Aerosolized
SRT to Treat Neonatal Respiratory Failures
January 4, 2005
Discovery Laboratories Announces Conference Call and Webcast
|
